Sodium thiosulphate treatment of uraemic tumoral calcinosis

Objective. The objective of this study was to describe the efficacy of sodium thiosulphate (STS) in tumoral calcinosis (TC). Methods. The methodology involved the reporting of four retrospective case reports of TC complicating end-stage renal disease (ESRD). Results. We investigated STS treatment in four patients (two men; ages 46-70 years) with TC. ESRD was secondary to nephronophthisis (n = 1), membranoproliferative glomerulonephritis (n = 1), diabetic nephropathy (n = 1), and thrombotic microangiopathy (n = 1). TC developed 3-28 years after dialysis began and resulted in articular pain (n = 4) and stiffness (n = 1). It involved shoulders and hips and was diffuse in one patient. Several treatments were tried without success. STS 12.5-25 g was given intravenously after each dialysis session for 11-14 months. Pain and stiffness rapidly disappeared and TC showed partial or total regression. Side effects during infusion included increased blood pressure (n = 1), nausea (n = 1) and vomiting (n = 1). TC did not recur after treatment discontinuation with follow-up of 1.5-12 years. Conclusion. STS showed promising efficacy in this short series of TC. Further studies are warranted.